Avalo Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 19
- Market Cap
- -
- Website
- http://www.avalotx.com
- Introduction
Avalo Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer
• Avalo Therapeutics has appointed Jennifer Riley as Chief Strategy Officer, effective January 1, 2025, to lead corporate strategy and product pipeline planning.
• Riley brings over 20 years of experience in the biotech and pharmaceutical industries, including leadership roles at Biogen and her own consulting firm, Northbrook Consulting.
• Her focus will be on advancing AVTX-009, an anti-IL-1β monoclonal antibody, currently in Phase 2 trials for hidradenitis suppurativa (HS), and exploring its expansion into other indications.
• Avalo's Board of Directors approved the grant to Ms. Riley of a non-qualified stock option awarded to purchase 150,000 shares of its common stock, vesting over four (4) years.
© Copyright 2025. All Rights Reserved by MedPath